Bluesight, the leader in hospital intelligence solutions, has officially published the findings from its 11th annual Hospital Pharmacy Operations Report (HPOR).
Going by the available details, this particular report surveyed a total of 258 hospital pharmacy participants during the first quarter. It did so to effectively assess opinions on current challenges, priorities, and trends shaping hospital pharmacies nationwide.
From the given surveyed lot, over 53.5% of respondents also boasted a decade or more of hospital pharmacy experience, as well as a diverse set of perspectives across pharmacy management (20%), diversion specialists (13%), pharmacy buyers (13%), and many more.
Talk about the published results on a slightly deeper level, we begin from how streamlining pharmacy purchasing to address top procurement challenges is tipped to increase in priority, with 95% of respondents noting it as important or very important compared to just 72% last year. On top of that, 75% of respondents also reported purchasing from four to nine different sources, further highlighting the need for streamlined purchasing workflows.
Next up, we must dig into a fact that most respondents (76%) expect an increase in 340B regulatory oversight over the next 2-3 years. Having said so, there remains a need to be more thoroughly prepared for audits, if the said element is to be realized at scale.
Another detail worth a mention here relates to drug diversion emerging as a top issue across the wider pharmaceutical space. We get to say so because 66% of respondents reported a diversion event within the past year. Markedly enough, diversion monitoring software discovered 42% of these events, more than any other discovery method.
Beyond that, Bluesight’s reports found smart pumps, IV prep tracking/clean room automation, and automated dispensing cabinets (ADCs) to be among the top three areas for tech investment in 2025.
As pharmacies support remote locations, Bluesight found that standardization and increased visibility were deemed as key factors to help close the gaps between enhanced visibility and limited financial resources, all for the purpose of implementing necessary solutions. This came after 41% of respondents reported no visibility into oncology inventory in remote locations, whereas on the other hand, only 38% reported allocating capital expenditures to improve inventory visibility.
Founded in 2011, Bluesight’s rise up the ranks stems from supporting hospital operations with unprecedented intelligence which, on its part, simplifies inventory management, procurement, and compliance. The company currently leverages a suite of industry-leading solutions to ensure that health systems protect every patient and optimize every dollar. Bluesight’s excellence in what it does can also be understood once you consider more than 2,400 United States and Canadian hospitals rely on it every day to achieve efficient and safe operations.
“Hospitals are currently navigating a wide variety of challenges surrounding an unpredictable supply chain and regulatory issues,” said Kevin MacDonald, CEO and co-founder of Bluesight. “What the report highlights is a compelling opportunity for innovation in addressing these issues. Areas like 340B adherence and drug shortage management are not only critical for operational efficiency but present untapped potential for technological advancements. These are two key areas where we are focusing our efforts to drive innovation and deliver solutions to help hospitals reduce costs and achieve long-term stability.”
